388 related articles for article (PubMed ID: 11187226)
1. [New drugs for substitution treatment of opioid dependence. Buprenorphine and 1-alpha-acetylmethadol (LAAM) ].
Petersen H; Skauge L; Svejsø J; Ege PP
Ugeskr Laeger; 2000 Nov; 162(48):6553-6. PubMed ID: 11187226
[TBL] [Abstract][Full Text] [Related]
2. Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
Eissenberg T; Stitzer ML; Bigelow GE; Buchhalter AR; Walsh SL
J Pharmacol Exp Ther; 1999 May; 289(2):936-45. PubMed ID: 10215673
[TBL] [Abstract][Full Text] [Related]
3. Clinical treatment of opioid addiction and dependence.
Ling W; Rawson RA; Compton M
Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
[No Abstract] [Full Text] [Related]
4. Discriminative stimulus effects of l-alpha-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys.
Brandt MR; Cabansag SR; France CP
J Pharmacol Exp Ther; 1997 Aug; 282(2):574-84. PubMed ID: 9262317
[TBL] [Abstract][Full Text] [Related]
5. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE
Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759
[TBL] [Abstract][Full Text] [Related]
6. Treatment considerations in the opioid dependent patient.
Wartenberg AA
Med Health R I; 1999 Mar; 82(3):91-4. PubMed ID: 10193138
[No Abstract] [Full Text] [Related]
7. Effect of opioid substitution therapy on alcohol metabolism.
Clark NC; Dietze P; Lenné MG; Redman JR
J Subst Abuse Treat; 2006 Apr; 30(3):191-6. PubMed ID: 16616162
[TBL] [Abstract][Full Text] [Related]
8. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
[TBL] [Abstract][Full Text] [Related]
9. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
Johnson RE; Chutuape MA; Strain EC; Walsh SL; Stitzer ML; Bigelow GE
N Engl J Med; 2000 Nov; 343(18):1290-7. PubMed ID: 11058673
[TBL] [Abstract][Full Text] [Related]
10. Effects of LAAM and methadone utilization in an opiate agonist treatment program.
Valdivia JF; Khattak S
Mt Sinai J Med; 2000; 67(5-6):398-403. PubMed ID: 11064490
[TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction.
Wolstein J; Gastpar M; Finkbeiner T; Heinrich C; Heitkamp R; Poehlke T; Scherbaum N
Pharmacopsychiatry; 2009 Jan; 42(1):1-8. PubMed ID: 19153939
[TBL] [Abstract][Full Text] [Related]
12. l-alpha-Acetylmethadol, l-alpha-acetyl-N-normethadol and l-alpha-acetyl-N,N-dinormethadol: comparisons with morphine and methadone in suppression of the opioid withdrawal syndrome in the dog.
Vaupel DB; Jasinski DR
J Pharmacol Exp Ther; 1997 Nov; 283(2):833-42. PubMed ID: 9353405
[TBL] [Abstract][Full Text] [Related]
13. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial.
Wedam EF; Bigelow GE; Johnson RE; Nuzzo PA; Haigney MC
Arch Intern Med; 2007 Dec; 167(22):2469-75. PubMed ID: 18071169
[TBL] [Abstract][Full Text] [Related]
14. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine.
Ling W; Rawson RA; Compton MA
J Psychoactive Drugs; 1994; 26(2):119-28. PubMed ID: 7931856
[TBL] [Abstract][Full Text] [Related]
15. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
16. Cross-tolerance and mu agonist efficacy in pigeons treated with LAAM or buprenorphine.
Galici R; McMahon LR; France CP
Pharmacol Biochem Behav; 2005 Jul; 81(3):626-34. PubMed ID: 15946731
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
18. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine maintenance therapy hinders acute pain management in trauma.
Harrington CJ; Zaydfudim V
Am Surg; 2010 Apr; 76(4):397-9. PubMed ID: 20420250
[TBL] [Abstract][Full Text] [Related]
20. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
Stock C; Shum JH
J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
